Dr. Marc Lemonnier, co-founder and CEO of Antabio, will participate in a BioPharma Dealmakers webcast, sponsored in part by Antabio, featuring five companies innovating antibiotic technologies. The webcast, part of the BioPharma Dealmakers series, is scheduled for 8AM PST, 11AM EST, 4PM GMT, 5PM CET on March 9. The webcast will explore some of the technologies and companies tackling the emerging antibiotic resistance crisis.
Antabio signs the Industry call for new antimicrobial business models presented at the World Economic Forum, Davos
On January 21, 2016, the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance was launched at an event at the World Economic Forum in Davos, Switzerland. This was drafted, agreed and signed by ANTABIO among 85 companies and nine industry associations from across the global pharmaceutical, diagnostics and biotechnology industries in 18 different countries.
ANTABIO receives €4 Million to develop new drugs to treat chronic infections in Cystic Fibrosis patients
Antabio SAS, a leading biopharmaceutical company in the field of antibacterial drug discovery, announced today that it has received a Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of chronic Pseudomonas infections in Cystic Fibrosis (CF) patients.
CF is the most common lethal, hereditary disease in Caucasian populations, affecting 1 in every 3,500 births in Europe with a current life expectancy of about 38 years among CF sufferers.
Antabio is now a member of the newly launched Alliance of Biotechs of Europe innovating in Anti-Microbial Resistance, called the BEAM Alliance. This group of European biotechnology companies is committed to tackling the unique challenges facing the industry in the antibacterial field and currently regroups 34 companies from 10 European countries.
Antabio awarded EUR 1 million funding from Bpifrance to support the discovery of New Gram-Negative Anti-Infective Agents
Antabio SAS, a French antibacterial drug discovery company, and Bpifrance, announce that Antabio will receive EUR 1 million in funding to support its Antibiotic Adjuvant Factory (“The Factory”) dedicated to the discovery and development of new antibacterial treatments. These funds will be used to discover compounds targeting key mechanisms of bacterial pathogenicity that will be co-administered with antibiotics to enhance their effectiveness against multi drug-resistant bacteria that cause severe human and animal diseases.
Organised by the French Senate and the ESSEC business school since 1999, Tremplin Entreprises is the most prestigious business plan contest for innovative companies in France. This is the third national award received by Antabio in less than a year, after the Septuors 2014 and the Concours Mondial de l’Innovation 2030. Co-organisé par le Sénat et l’ESSEC depuis 1999, Tremplin Entreprises est un concours national pour les entreprises innovantes en France.
Antabio receives funding from the Midi-Pyrénées Region to support the expansion of its R&D capabilities
Antabio announces that it will receive EUR 90,000 in funding from the Midi-Pyrénées Region to support the expansion of its R&D capabilities in Labège. This funding will be awarded to Antabio under the Innovative SMEs Support Contracts scheme (“Contrat d’Appui PME Innovation”) operated by the French EU-Region Midi-Pyrénées.
Antabio announces that it has been awarded the “Concours Mondial de l’Innovation 2030” Worldwide Innovation Challenge for its new discovery program focused on the treatment of chronic infections in cystic fibrosis (CF) patients. Antabio annonce que son projet de découverte de nouveaux traitements pour les patients atteints de mucoviscidose a été primé par le Concours Mondial de l’Innovation 2030.
Antabio’s profile is featured in a double-page article of the June 2014 special issue on infectious diseases of Nature Biopharma Dealmakers.
The article describes the company’s history since its inception featuring some of its most innovative achievements, including the first successful round of crowdfunding applied to biotech start-up financing.
Argenta and Antabio Announce Achievement of Milestone in their Anti-bacterial Drug Discovery Collaboration
Novel lead series of pan-metallo beta-lactamase inhibitors identified. Harlow, UK and Labège, France, 10th March 2014: Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug discovery project funded by the Wellcome Trust.